Loading...
•
Dec 31, 2023
Zomedica Q4 2023 Earnings Report
Reported record revenue and annual growth, driven by diagnostics and therapeutic devices segments.
Key Takeaways
Zomedica reported a record fourth quarter with revenue of $7.3 million, contributing to a full-year revenue of $25.2 million, a 33% increase from the previous year. The growth was primarily driven by the Therapeutic Devices segment and the Diagnostics segment. The company's liquidity stood at $100.5 million.
Fourth quarter revenue grew by 19% to $7.3 million.
Full year revenue grew by 33% to $25.2 million.
Gross margin was 69% for both the fourth quarter and the full year 2023.
Cash, cash equivalents, and available-for-sale securities were $100.5 million as of December 31, 2023.
Revenue by Segment
Forward Guidance
Zomedica expects full year revenue in the range of $31 to $35 million for 2024.
Positive Outlook
- Growth in 2024 will be driven by its existing portfolio, including recently launched products.
- Supported by investments the Company is making to continue to drive increased adoption and utilization of its products.
- Driven by contributions from a number of new products that the Company expects to launch during 2024.
- Revenues to increase, driven by synergies derived from expanded product lines
- Revenues to increase, driven by increased sales/ marketing/commercialization efforts, and the move to full sales territory deployment, execution and maturation.
Challenges Ahead
- Guidance for 2024 does not incorporate any positive benefits from acquisitions the Company may make during the year.
- The outcome of clinical studies
- The application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...